$EXEL

Aftab Dana sold $2.2M of EXEL

Aftab Dana (EVP, Research and Development) sold 43,451 shares of EXELIXIS, INC. (EXEL) at $50.35 ($2.19M total) on 2026-05-26.

Original reporting
SEC EDGAR · Aftab Dana
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

Aftab Dana, EVP Research and Development, sold $2.19M of EXEL shares in an open-market transaction; the disclosure may slightly influence sentiment but does not introduce new operational or financial information about EXEL.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The absence of a stated 10b5-1 plan could raise speculation, but the filing provides no rationale for the sale or any link to upcoming catalysts.

Relevance 6/10Novelty 3/10Timing: Filed 2026-05-28, transaction dated 2026-05-26.

Background

The article is a SEC Form 4 insider transaction disclosure for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

EXELIXIS Form 4 shows EVP R&D Aftab Dana sold 43,451 shares at $50.35 on 2026-05-26 for about $2.19M.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than thesis-changing.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales are often liquidity-driven and may not reflect negative expectations, especially without any other negative company-specific disclosures.

Key entities

  • EXELIXIS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Aftab Dana

    EVP, Research and Development who sold 43,451 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMed

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis (EXEL) announced a 3-month FDA review extension for zanzalintinib, now targeting March 3, 2027. The FDA requested updated safety and efficacy data. The drug, combined with atezolizumab, aims to treat metastatic colorectal cancer. Exelixis' approval prospects hinge on the full STELLAR-303 study data, which showed a statistically significant survival benefit in the overall population but not in a key subgroup.

$EXELMedAI 8/10

Does Extended FDA Review Change The Bull Case For Exelixis (EXEL)?

Exelixis (EXEL) announced a 3-month FDA review extension for its zanzalintinib plus atezolizumab NDA, moving the decision date to March 3, 2027. The delay is due to updated safety and efficacy data. Analysts highlight the impact on Exelixis' investment narrative, with near-term focus on the colorectal cancer decision. The company aims for $3.3B revenue and $1.3B earnings by 2029, with risks tied to CABOMETYX concentration and margin pressures.

$EXELMed

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (EXEL) reported slower-than-expected revenue growth for CABOMETYX due to delayed treatment decisions in NET. The company maintains 47% new-patient market share and plans to launch zanza for colorectal cancer if approved. Exelixis expects CABOMETYX generics in 2031 and is investing in pipeline and share repurchases, with $600M remaining under its authorization.

$EXELLow

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

The FDA extended its review of Exelixis' NDA for zanzalintinib plus atezolizumab to treat metastatic colorectal cancer, moving the PDUFA action date to March 3, 2027. The extension followed updated safety and efficacy data submission, classified as a major amendment. The NDA is supported by the STELLAR-303 trial, which showed a median OS of 10.9 months vs 9.4 months with regorafenib.